Optimizing vaccine allocation at different points in time during an epidemic

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Matrajt, Laura ^a   Longini Jr , Ira M ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; CONTROLLED STUDY; DEVELOPED COUNTRY; EPIDEMIC; HEALTH CARE POLICY; HIGH RISK POPULATION; HOSPITALIZATION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MORTALITY; POPULATION RESEARCH; VIRUS TRANSMISSION; ADULT; ALGORITHM; BIOLOGICAL MODEL; CHILD; DEVELOPING COUNTRY; DISEASE TRANSMISSION; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; METHODOLOGY; TIME; VACCINATION;

ADULT; ALGORITHMS; CHILD; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; EPIDEMICS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; TIME FACTORS; VACCINATION;

EID: 78649731027     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013767     Document Type: Article

References (34)

1. GlaxoSmithKline (2009) GlaxoSmithKline update: Government orders for pandemic (H1N1) 2009 vaccine. http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10104.htm. last accesed March 05, 2010.
2. US Department of Health and Human Services. HHS 2009 H1N1 Vaccine Development Activities. https://www.medicalcountermeasures.gov/BARDA/MCM/panflu/factsheet.aspx. last accesed March 05, 2010.
3. WHO (2009) Production and availability of pandemic influenza A (H1N1) vaccines. www.who.int/csr/disease/swineflu/frequently_asked_questions/vaccine_prep aredness/production_availability/en/index.html. Accesed July 28th, 2009.
4. Monto AS, Davenport FM, Napier JA, Francis TJ (1970) Modification of an outbreak of influenza in tecumseh, michigan by vaccination of schoolchildren. J Infect Dis 122: 16-25.
5. Longini I, Halloran M (2005) Strategy for distribution of influenza vaccine to highrisk groups and children. American Journal of Epidemiology 161: 303-306.
6. Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, et al. (2005) Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 116: e397-407.
7. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, et al. (2001) The japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 344: 889-896.
8. Goldstein E, Apolloni A, Lewis B, Miller JC, Macauley M, et al. (2010) Distribution of vaccine/antivirals and the 'least spread line' in a stratified population. J R Soc Interface 7: 755-764.
9. Medlock J, Meyers LA (2009) Optimizing allocation for a delayed influenza vaccination campaign. PLoS Curr Influenza. pp RRN1134.
10. Tuite A, Fisman DN, Kwong JC, Greer A (2010) Optimal pandemic influenza vaccine allocation strategies for the canadian population. PLoS Curr Influenza. pp RRN1144.
11. Gojovic MZ, Sander B, Fisman D, Krahn MD, Bauch CT (2009) Modelling mitigation strategies for pandemic (H1N1) 2009. CMAJ 181: 673-680.
12. Sypsa V, Pavlopoulou I, Hatzakis A (2009) Use of an inactivated vaccine in mitigating pandemic influenza A(H1N1) spread: a modelling study to assess the impact of vaccination timing and prioritisation strategies. Euro Surveill 14: 19356.
13. US Census Bureau (2010) Fact sheets. http://www.census.gov. URL\{Error! Hyperlink reference not valid. last accesed Nov. 24th, 2009.
14. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. World Population Prospects: The 2008 Revision. http://esa.un.org/unpp. last accesed March 05, 2010.
15. Halloran ME, Struchiner CJ, Longini IM (1997) Study designs for evaluating different efficacy and effectiveness aspects of vaccines. American Journal of Epidemiology 146: 789-803.
16. National Institute of Allergy and Infectious Diseases, National Institutes of Health (2009) Early Results: In Children, 2009 H1N1 Influenza Vaccine Works Like Seasonal Flu Vaccine. http://www3.niaid.nih.gov/news/newsreleases/2009/H1N1PedTrial.htm.
17. National Institute of Allergy and Infectious Diseases, National Institutes of Health (2009) Updated Results: In Youngest Children, a Second Dose of 2009 H1N1 Influenza Vaccine Elicits Robust Immune Response. Updated Results: In Youngest Children, a Second Dose of 2009 H1N1 Influenza Vaccine Elicits Robust Immune Response.
18. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M (2010) Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 375: 41-48.
19. Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, et al. (2010) Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 303: 37-46.
20. World Development Indicators database. Mortality statistics. http://www.nationmaster.com/graph/mor_rat_adu_fem_per_1000_fem_adu-femal e-per-1-000-adults. last accessed April 2009.
21. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, et al. (2009) Pandemic potential of a strain of influenza A (H1N1): early findings. Science 324: 1557-1561.
22. Yang Y, Sugimoto JD, Halloran ME, Basta NE, Chao DL, et al. (2009) The transmissibility and control of pandemic influenza A (H1N1) virus. Science 326: 729-733.
23. Balcan D, Hu H, Goncalves B, Bajardi P, Poletto C, et al. (2009) Seasonal transmission potential and activity peaks of the new influenza A(H1N1): a Monte Carlo likelihood analysis based on human mobility. BMC Med 7: 45.
24. Diekmann O, Heesterbeek J, Metz J (1990) On the definition and computation of the basic reproduction ratio R0 in models for infectious-diseases in heterogeneous populations. Journal of Mathematical Biology 28: 365-382.
25. van den Driessche P, Watmough J (2002) Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Mathematical Biosciences 180: 29-48.
26. Brauer F, van den Driessche P, Wu J, eds. (2008) Mathematical Epidemiology, volume 1945 of Lecture Notes in Mathematics. Springer.
27. WHO (2010) WHO takes action on pandemic (H1N1) 2009. http://www.who.int/csr/disease/swineflu/action/en/index.html. last accessed June 2010.
28. Centers for Disease Control and Prevention (2010) Interim Results: Influenza A (H1N1) 2009 Monovalent Vaccination Coverage United States, October- December 2009. MMWR Morb Mortal Wkly Rep 58: 1009-1012.
29. Dushoff J, Plotkin JB, Viboud C, Simonsen L, Miller M, et al. (2007) Vaccinating to protect a vulnerable subpopulation. PLoS Med 4: e174.
30. Bansal S, Pourbohloul B, Meyers LA (2006) A comparative analysis of influenza vaccination programs. PLoS Med 3: e387.
31. Medlock J, Galvani AP (2009) Optimizing Influenza Vaccine Distribution. Science 325: 1705-1708.
32. Tennenbaum S (2008) Simple criteria for finding (nearly) optimal vaccination strategies. Journal of Theoretical Biology 250: 673-683.
33. Mylius SD, Hagenaars TJ, Lugner AK, Wallinga J (2008) Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine 26: 3742-3749.
34. Wallinga J, van Boven M, Lipsitch M (2010) Optimizing infectious disease interventions during an emerging epidemic. Proc Natl Acad Sci U S A 107: 923-928.